(Q39367983)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

11 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer (English)

1 reference

11 September 2017

0 references

1 reference

Jie Chen

1

1 reference

11 September 2017

Bo Xi

2

1 reference

11 September 2017

Yueran Zhao

3

1 reference

11 September 2017

Yang Yu

4

1 reference

11 September 2017

Jie Zhang

5

1 reference

11 September 2017

Chunyu Wang

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

6 April 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

126

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

109-117

1 reference

11 September 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Long-term results and prognostic factors in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

The biology of ovarian cancer: new opportunities for translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

A perspective on cancer cell metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Identification of the core-histone-binding domains of HMG1 and HMG2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

HMGB1 and RAGE in inflammation and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

RAGE and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Targeting HMGB1 in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

High Mobility Group Box 1 Release from Hepatocytes during Ischemia and Reperfusion Injury Is Mediated by Decreased Histone Deacetylase Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

HMGB1, a potent proinflammatory cytokine in sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Masquerader: high mobility group box-1 and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

High-mobility group box 1 and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

HMGB1: a two-headed signal regulating tumor progression and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Emerging roles of proteases in tumour suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

Growth suppression and radiosensitivity increase by HMGB1 in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.051

The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer

7 January 2021

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.YGYNO.2012.03.051

Identifiers

DOI

10.1016/J.YGYNO.2012.03.051

1 reference

11 September 2017

1 reference